American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders, 5th Edition.Washington, DC: American Psychiatric Publishing.
2.
BlackNStockingsECampbellG, et al. (2019) Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: A systematic review and meta-analysis. The Lancet Psychiatry6: 995–1010.
3.
BrunoCHavardAGilliesMB, et al. (2023) Patterns of attention deficit hyperactivity disorder medicine use in the era of new non-stimulant medicines: A population-based study among Australian children and adults (2013–2020). Australian & New Zealand Journal of Psychiatry57: 675–685.
4.
DarkeSLappinJFarrellM (2019) The Clinician’s Guide to Illicit Drugs and Health. Sutton: Silverback Publishing.
5.
LappinJMSaraGE (2019) Psychostimulant use and the brain. Addiction114: 2065–2077.
6.
LappinJMSaraGEFarrellM (2017) Methamphetamine-related psychosis: An opportunity for assertive intervention and prevention. Addiction112: 927–928.
7.
MoranLVOngurDHsuJ, et al. (2019) Psychosis with methylphenidate or amphetamine in patients with ADHD. New England Journal of Medicine380: 1128–1138.
8.
MurrieBLappinJLargeM, et al. (2020) Transition of substance-induced, brief, and atypical psychoses to schizophrenia: A systematic review and meta-analysis. Schizophrenia Bulletin46(3): 505–516.
9.
National Institute for Health and Care Excellence (NICE) (2018) Attention Deficit Hyperactivity Disorder: Diagnosis and Management. London: NICE.
